Results 11 to 20 of about 40,773 (330)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis

Archives of Medical Science, 2021
Introduction The aim of the study was to study a nanoliposomal anti-PCSK9 vaccine as a novel approach for cholesterol lowering via PCSK9 inhibition. Material and methods An immunogenic peptide construct termed immunogenic fused PCSK9-tetanus (IFPT) was ...
Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Mohammad Afshar, Maciej Banach, Amirhossein Sahebkar   +4 more
doaj   +1 more source

Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study

Arthritis Research & Therapy, 2023
Background In addition to decreasing the level of cholesterol, proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has pleiotropic effects, including immune regulation. However, the impact of PCSK9 on autoimmune diseases is controversial. Therefore,
Weijia Xie, Jiaxin Li, H. Du, Jian Xia
semanticscholar   +1 more source

SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells

Theranostics, 2023
Background: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (i) are a class of lipid-lowering drugs suggested to hold a plethora of beneficial effects independent of their LDL cholesterol-lowering properties.
N. D’Onofrio, F. Prattichizzo, R. Marfella, C. Sardu, Elisa Martino, L. Scisciola, Lorenza Marfella, Rosalba La Grotta, Chiara Frigé, G. Paolisso, Antonio Ceriello, M. Balestrieri   +11 more
semanticscholar   +1 more source

Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function. [PDF]

PLoS ONE, 2015
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that directs membrane-bound receptors to lysosomes for degradation. In the most studied example of this, PCSK9 binding leads to the degradation of low density lipoprotein receptor
Rachel M DeVay, Lynn Yamamoto, David L Shelton, Hong Liang   +3 more
doaj   +1 more source

Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target

Nature Genetics, 2023
Genome-wide association meta-analysis of AAA identifies 121 independent risk loci and highlights potential therapeutic targets such as proprotein convertase, subtilisin/kexin-type 9 (PCSK9).
Tanmoy Roychowdhury, D. Klarin, M. Levin, J. Spin, YaeHyun Rhee, Alicia Deng, Colwyn A. Headley, N. Tsao, C. Gellatly, V. Zuber, Fred Shen, W. Hornsby, I. H. Laursen, S. Verma, A. Locke, G. Einarsson, G. Thorleifsson, Sarah E. Graham, O. Dikilitas, Jack W. Pattee, R. Judy, Ferran Pauls-Verges, Jonas B. Nielsen, B. Wolford, B. Brumpton, Jaume Dilmé, O. Peypoch, Laura Calsina Juscafresa, Todd L. Edwards, Dadong Li, K. Banasik, S. Brunak, R. L. Jacobsen, Minerva T. Garcia-Barrio, Jifeng Zhang, Lars M. Rasmussen, Regent Lee, A. Handa, A. Wanhainen, K. Mani, J. Lindholt, L. M. Obel, E. Strauss, G. Oszkinis, Christopher P. Nelson, K. Saxby, J. V. van Herwaarden, S. W. van der Laan, J. van Setten, Mercedes Camacho, Frank M. Davis, Rachael Wasikowski, L. Tsoi, J. Gudjonsson, J. Eliason, Dawn M. Coleman, Peter K. Henke, S. Ganesh, Y. E. Chen, Weihua Guan, J. Pankow, Nathan Pankratz, O. Pedersen, C. Erikstrup, Weihong Tang, K. Hveem, D. Gudbjartsson, S. Gretarsdottir, U. Thorsteinsdóttir, H. Hólm, K. Stefánsson, M. Ferreira, A. Baras, I. Kullo, Marylyn D. Ritchie, A. Christensen, K. Iversen, Nikolaj Eldrup, Henrik H. Sillesen, S. Ostrowski, H. Bundgaard, H. Ullum, Stephen Burgess, D. Gill, Katherine A. Gallagher, M. Sabater-Lleal, Frank Nilesh J. Dudbridge Samani, F. Dudbridge, Nilesh J. Samani, I. Surakka, Gregory T. Jones, M. Bown, P. Tsao, Cristen J. Willer, S. Damrauer   +94 more
semanticscholar   +1 more source

Inhibitors of PCSK9 [PDF]

Revue medicale suisse, 2017
Observational data show a consistent association between elevated low density lipoproteins (LDL-C) and cardiovascular disease (CVD). Reduction of LDL-C reduces the risk of CVD as has been shown by many trials. Statins are currently the most effective drugs for lowering LDL-C, but can present side effects which might limit the prescribed dosage and ...
Petrova-Slater, Iveta, Denegri, Andrea, Pasotti, Elena, Rossi, Maria Grazia, Spirk, David, Riesen, Walter F, Moccetti, Tiziano, Moccetti, Marco   +7 more
openaire   +2 more sources

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Circulation, 2023
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite ...
D. Johns, Louis-Charles Campeau, Puja Banka, An Bautmans, T. Bueters, E. Bianchi, Danila Branca, P. Bulger, Inne Crèvecoeur, F. Ding, R. Garbaccio, Erik D. Guetschow, Yan Guo, Sookhee N. Ha, Jennifer M. Johnston, H. Josien, E. Kauh, K. Koeplinger, Jeffrey T. Kuethe, E. Lai, C. Lanning, Anita Y. H. Lee, L. Li, Anilkumar G. Nair, E. O’neill, S. Stoch, D. Thaisrivongs, T. Tucker, Petr Vachal, K. van Dyck, F. Vanhoutte, Bram Volckaert, Dennis G. Wolford, An-Wu Xu, T. Zhao, Dan Zhou, Susan Zhou, Xiaohong Zhu, Hratch J. Zokian, Abbas M. Walji, H. Wood   +40 more
semanticscholar   +1 more source

Pro-inflammatory Vascular Stress in Spontaneously Hypertensive Rats Associated With High Physical Activity Cannot Be Attenuated by Aldosterone Blockade

Frontiers in Cardiovascular Medicine, 2021
The effect of high physical activity, performed as voluntary running wheel exercise, on inflammation and vascular adaptation may differ between normotensive and spontaneously hypertensive rats (SHRs). We investigated the effects of running wheel activity
Rolf Schreckenberg, Annemarie Wolf, Christian Troidl, Sakine Simsekyilmaz, Klaus-Dieter Schlüter   +4 more
doaj   +1 more source

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study

PLoS Medicine, 2023
Background Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be ...
S. Fang, J. Yarmolinsky, D. Gill, C. Bull, C. Perks, G. Davey Smith, T. Gaunt, T. Richardson   +7 more
semanticscholar   +1 more source

Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis

Frontiers in Physiology, 2023
Familial hypercholesterolemia (FH) is a globally underdiagnosed genetic condition associated with premature cardiovascular death. The genetic etiology data on Arab FH patients is scarce.
Noor Ahmad Shaik, Noor Ahmad Shaik, Najla Al-Shehri, Mohammad Athar, Mohammad Athar, Ahmed Awan, Mariam Khalili, Hadiah Bassam Al Mahadi, Gehan Hejazy, Omar I. Saadah, Sameer Eida Al-Harthi, Ramu Elango, Ramu Elango, Babajan Banaganapalli, Babajan Banaganapalli, Eman Alefishat, Eman Alefishat, Eman Alefishat, Zuhier Awan   +18 more
doaj   +1 more source